Clinical trials: Anger
Menopausal; Crisis, Self-Compassion
Mindfulness-Based Self-Compassion Training for Menopausal Women
This study was conducted to determine the effects of mindfulness-based self-compassion training for menopausal women on their genital self-image and self-anger.
- Conditions
- Menopausal; Crisis, Self-Compassion, Image, Body, Anger
- Trial name
- NCT06942169
- Testing
- Mindfulness-Based Self-Compassion Training
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Tarsus University
Healthy Volunteers
A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants
ZM-H1505R is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing.
- Trial name
- NCT04220801
- Testing
- ZM-H1505R
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Healthy Subjects
A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy Volunteers
This a double blind, randomized, placebo controlled, single and multiple ascending dose (SAD/MAD) study in healthy subjects. Safety evaluation will include adverse events (TEAEs), clinical laboratory values, vital signs, ECGs…
- Trial name
- NCT03879928
- Testing
- Single ascending doses of FM101, Multiple ascending doses of FM101, Food effects of FM101
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Future Medicine
Cystic Fibrosis
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)
The present study is designed to assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects.
- Trial name
- (SNO-9) (NCT02934139)
- Testing
- Cavosonstat
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Nivalis Therapeutics, Inc.
Healthy Volunteers
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
A phase 1 study in healthy volunteers (female and male) to evaluate through SAD and MAD, the safety, PK, PD and immunogenicity of ARGX-113 administered intravenously.
- Trial name
- NCT03457649
- Testing
- ARGX-113
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- argenx
Atopic Dermatitis
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes including gene expression, protein degradation, and multiple cellular stress responses.
- Trial name
- NCT05215808
- Testing
- RBN-3143
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ribon Therapeutics, Inc.
Alzheimer Disease
A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127
This is a phase 1 randomized double blind, first in human (FIH) study with the novel oral Alzheimer drug candidate REM0046127, which consists of two main parts, a single ascending dose (SAD) study with 7 cohorts followed by a…
- Trial name
- NCT04672135
- Testing
- REM0046127
- Where
- Austria
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- reMYND
Bacterial Infections
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects.
- Trial name
- NCT02955459
- Testing
- VNRX-5133
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
- Trial name
- NCT03646721
- Testing
- DA-1241, Sitagliptin
- Where
- 4 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Hepatitis B
First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
This study is a Phase 1, randomized, double-blind (Sponsor unblinded), placebo controlled, dose escalation study to determine the safety, tolerability and pharmacokinetics (PK) profile of GSK3389404 as single (Part 1) and…
- Trial name
- NCT02647281
- Testing
- GSK3389404
- Where
- 2 sites in United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anxiety Depression, Alcohol Abuse
CBD Oil for Reducing Emotional Impact of COVID-19
Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg.
- Conditions
- Anxiety Depression, Alcohol Abuse, Substance Abuse, Anger
- Trial name
- CBDOIL (NCT04603781)
- Testing
- CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Healthy Volunteers
Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects
The purpose of this study is to determine whether the drug UE2343, a potential treatment for Alzheimer's Disease (AD), is effective by assessing safety, tolerability, pharmacokinetics and pharmacodynamics in a Multiple Ascending…
- Trial name
- NCT02616445
- Testing
- UE2343
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical
Aggression, Anger
Hostile Bias Modification Training Online Study II
The purpose of this study is to see how people respond on a word completion task relates to how they behave and respond to situations in the real world. This is a two part research study.
- Conditions
- Aggression, Anger, Emotion Regulation, Self-Control
- Trial name
- HBMT II (NCT04015440)
- Testing
- HBMT, Other Training
- Where
- United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Anxiety State, COVID-19
Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives
The purpose of the investigators is to study the psychological impact of the COVID-19 lockdown on the members of the Ville Evrard Hospital staff and their close relatives, and to identify potential lockdown conditions that could…
- Conditions
- Anxiety State, COVID-19, Isolation, Social, Health Personnel Attitude
- Trial name
- ICOS (NCT04357418)
- Testing
- it is a survey
- Where
- France
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
- Trial name
- NCT04350736
- Testing
- TD-0903
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Healthy
AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)
The purpose of this study is to determine the safety of AZD6765 when given in single and multiple oral doses and to compare an oral and intravenous (IV) formulation of AZD6765 to placebo.
- Trial name
- NCT00963365
- Testing
- AZD6765
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia, Alzheimer's Disease Psychosis
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable…
- Trial name
- NCT07230652
- Testing
- LY03020
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Healthy Subjects
Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects
The study included three clinical studies, namely a single ascending dose (SAD) study, a multiple ascending dose (MAD) study, and a high-fat diet food effect (FE) study.
- Trial name
- NCT07394452
- Testing
- TJ0113 Capsules
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants
The primary objective of this study is to assess the safety and tolerability of a single dose and multiple doses of BIIB033 administered to healthy adult Japanese participants.
- Trial name
- NCT02641041
- Testing
- BIIB033
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biogen
Optic Neuritis, Optic; Neuritis, With Demyelination
BN201 SAD MAD Study in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects.
- Trial name
- NCT03630497
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Accure Therapeutics